Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer

NCT ID: NCT00868634

Last Updated: 2016-08-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 600 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-02-28
• Study Completion Date: 2015-10-31

Brief Summary

The aim of the trial is to detect the superiority of the triple combination of capecitabine, bevacizumab and vinorelbine versus the combination of capecitabine and bevacizumab in patients with metastatic breast cancer. 600 patients, 300 in each treatment group, are treated until progression of disease to determine PFS.

Conditions

Metastatic Breast Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

A

Capecitabine / Bevacizumab

Group Type: ACTIVE_COMPARATOR

capecitabine

Intervention Type: DRUG

1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.

bevacizumab

Intervention Type: DRUG

15 mg/kg i.v., day 1 Cycles are repeated every three weeks.

B

Capecitabine / Bevacizumab / Vinorelbine

Group Type: EXPERIMENTAL

capecitabine

Intervention Type: DRUG

1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.

bevacizumab

Intervention Type: DRUG

15 mg/kg i.v., day 1. Cycles are repeated every three weeks.

vinorelbine

Intervention Type: DRUG

25 mg/m2 i.v., days 1+8. Cycles are repeated every three weeks.

Interventions

capecitabine

1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.

Intervention Type: DRUG

bevacizumab

15 mg/kg i.v., day 1 Cycles are repeated every three weeks.

Intervention Type: DRUG

capecitabine

1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.

Intervention Type: DRUG

bevacizumab

15 mg/kg i.v., day 1. Cycles are repeated every three weeks.

Intervention Type: DRUG

vinorelbine

25 mg/m2 i.v., days 1+8. Cycles are repeated every three weeks.

Intervention Type: DRUG

Other Intervention Names

Xeloda®; Avastin®; Xeloda®; Avastin®; Navirel®

Eligibility Criteria

Inclusion Criteria

• Written informed consent.
• Able to comply with the protocol.
• ECOG Performance status 0 - 2.
• Life expectancy more than 12 weeks.
• Known ER / PR status.
• Confirmed HER2/neu-negative, adenocarcinoma of the breast with measurable or non-measurable locally recurrent or metastatic disease, who are candidates for chemotherapy.
• Previous (neo)adjuvant chemotherapy is allowed provided that the last dose of chemotherapy was applied more than 6 months prior to randomization.
• Previous adjuvant radiotherapy is allowed as part of the treatment of early breast cancer provided that no more than 30% of marrow-bearing bone was irradiated.
• No signs and symptoms of CHF.
• Adequate hepatic and renal function values.
• Adequate hematologic function values.

Exclusion Criteria

• Pregnant or lactating females.
• Previous chemotherapy for metastatic or locally recurrent breast cancer.
• Previous radiotherapy for the treatment of metastatic disease (unless given for the relief of metastatic bone pain)
• Evidence of spinal cord compression or current evidence of central nervous system (CNS) metastases.
• Major surgical procedure, open biopsy or significant traumatic in-jury within 28 days prior to randomization, or anticipation of the need for major surgery during the course of the study treatment.
• History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding.
• Uncontrolled hypertension (systolic > 150 mmHg and/or diastolic > 100 mmHg). Clinically significant (i.e. active) cardiovascular disease, requiring medication during the study and might interfere with regularity of the study treatment, or not controlled by medication.
• Non-healing wound, active peptic ulcer or bone fracture.
• History of abdominal fistula, or any grade 4 nongastrointestinal fistula, gastrointestinal perforation or intrabdominal abscess within 6 months of randomization.
• Active infection requiring i.v. antibiotics at randomization.
• Clinically significant malabsorption syndrome or inability to take oral medication.
• Known hypersensitivity to any of the study drugs or excipients.
• Concurrent treatment with any drug interfering with study medication. Concurrent participation in another clinical trial. Prior participation is allowed when the last study medication was applied more than 4 weeks prior to randomization.

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Arbeitsgemeinschaft fur Internistische Onkologie

OTHER

Sponsor Role: collaborator

Arbeitskreis Klinische Studien

OTHER

Sponsor Role: collaborator

Roche Pharma AG

INDUSTRY

Sponsor Role: collaborator

iOMEDICO AG

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Susanna Hegewisch-Becker, MD

Role: PRINCIPAL_INVESTIGATOR

Onkologische Schwerpunktpraxis Eppendorf

Locations

Onkologische Schwerpunktpraxis Eppendorf

Hamburg, , Germany

Countries

Germany

Other Identifiers

2008-003779-37

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

IOM-080-2

Identifier Type: -

Identifier Source: org_study_id